Zheng Quan Ri Bao Zhi Sheng·2025-10-14 12:09Core Insights - The 2025 Zhangjiang Pharmaceutical Valley Global Promotion Conference and International Innovation Conference has commenced, focusing on the full-cycle development system from source innovation to global market application [1][2] - Zhangjiang Pharmaceutical Valley has approved 29 first-class domestic new drugs, with seven innovative drugs set to launch in 2025, showcasing strong source innovation capabilities [1][2] - The establishment of the Zhangjiang Pharmaceutical Valley Comprehensive Service Center aims to enhance industry service capabilities and support the entire lifecycle of enterprises [2] Group 1 - The conference gathered leaders from the National Medical Products Administration, local governments, academicians, top scientists, industry leaders, and capital representatives to discuss the development of the pharmaceutical industry [1] - Seven innovative drugs from companies such as Inpai Pharmaceutical and Fuxing Pharmaceutical are expected to launch in 2025, including the first human-derived long-acting GLP-1 receptor agonist and the first gene therapy drug [1][2] - A total of 38 innovative medical device products have been approved, with four products from Xuan Yu Medical and Shang Yang Medical successfully launched in 2025, marking advancements in cardiac electrophysiology [1][2] Group 2 - Zhangjiang Pharmaceutical Valley has become a global platform for pharmaceutical innovation, with 11 global innovative drugs launched in China to date [2] - The Comprehensive Service Center integrates industry resources and provides a "1+1+1" service system, including a scientist salon, a results display center, and a one-stop service center [2] - The future focus will be on strengthening the entire innovation ecosystem, from source innovation to clinical application, to establish an internationally influential biopharmaceutical industry innovation hub [2]